India's drug regulator said on December 29 that it had inspected Marion Biotech's production facility and promised more action based on the probe report after the company's cough syrup was linked to the deaths of 18 children in Uzbekistan. A legal representative said Marion Biotech regretted the deaths and the company had halted production of the Doc-1 Max syrup. The drug regulator reviewed the company's Noida facility in Uttar Pradesh and is in regular touch with its Uzbek counterpart, the Indian Health Ministry said in a statement. To read the original story by Reuters, click here.
Editors' Picks
RFE/RL has been declared an "undesirable organization" by the Russian government.
If you are in Russia or the Russia-controlled parts of Ukraine and hold a Russian passport or are a stateless person residing permanently in Russia or the Russia-controlled parts of Ukraine, please note that you could face fines or imprisonment for sharing, liking, commenting on, or saving our content, or for contacting us.
To find out more, click here.